Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial

被引：0
|
作者：
Jotte, R. [1 ]
Conkling, P. R. [2 ]
Reynolds, C. [3 ]
Shah, C. [4 ]
Galsky, M. [5 ]
Klein, L.
Fitzgibbons, J. F. [6 ]
McNally, R. [7 ]
Oliver, J. W. [8 ]
Renschler, M. [8 ]
机构：
[1] Rocky Mt Canc Ctr US Oncol, Denver, CO USA
[2] Virginia Oncol Associates US Oncol, Norfolk, VA USA
[3] Ocala Oncol Ctr US Oncol, Ocala, FL USA
[4] SUNY Upstate Med Univ, Syracuse, NY USA
[5] Nevada US Oncol, Ctr Comprehens Canc, Las Vegas, NV USA
[6] Sacred Heart Med Ctr US Oncol, Spokane, WA USA
[7] Celgene Corp, Biostat, Summit, NJ USA
[8] Celgene Corp, Clin Dev, Summit, NJ USA
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71833-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：540 / 541
页数：2
相关论文
共 50 条
  • [41] CABAZITAXEL (CBZ) VS TOPOTECAN (TPT) IN PATIENTS (PTS) WITH SMALL CELL LUNG CANCER (SCLC) WITH PROGRESSIVE DISEASE DURING/AFTER FIRST-LINE (1L) TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY (CTX)
    Evans, T.
    Cho, B. C.
    Udud, K.
    Fischer, J. R.
    Shepherd, F. A.
    Martinez, P.
    Ramlau, R.
    Syrigos, K. N.
    Chadjaa, M.
    Wolf, M.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S28 - S29
  • [42] Outcomes of second-line chemotherapy in Japanese patients with small cell lung cancer previously treated with platinum-based chemotherapy
    Haruyasu, Murakami
    Naito, Tateaki
    Kaira, Kyoichi
    Tsuya, Asuka
    Nakamura, Yukiko
    Takahashi, Toshiaki
    Endo, Masahiro
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S817 - S818
  • [43] A phase II trial in patients with extensive disease small-cell lung cancer (ED-SCLC) with irinotecan, carboplatin and etoposide regimen as a front line treatment
    Syrigos, Konstantinos N.
    Charpidou, Andriani G.
    Pantazopoulos, Kosmas N.
    Dilana, Kalliopi
    Rigopoulou, Anna
    Georgatou, Niki
    Roussos, Charalampos
    ANNALS OF ONCOLOGY, 2006, 17 : 232 - 232
  • [44] Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
    Yan Sun
    Ying Cheng
    Xuezhi Hao
    Jie Wang
    Chengping Hu
    Baohui Han
    Xiaoqing Liu
    Li Zhang
    Huiping Wan
    Zhongjun Xia
    Yunpeng Liu
    Wei Li
    Mei Hou
    Helong Zhang
    Qingyu Xiu
    Yunzhong Zhu
    Jifeng Feng
    Shukui Qin
    Xiaoyan Luo
    BMC Cancer, 16
  • [45] Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
    Sun, Yan
    Cheng, Ying
    Hao, Xuezhi
    Wang, Jie
    Hu, Chengping
    Han, Baohui
    Liu, Xiaoqing
    Zhang, Li
    Wan, Huiping
    Xia, Zhongjun
    Liu, Yunpeng
    Li, Wei
    Hou, Mei
    Zhang, Helong
    Xiu, Qingyu
    Zhu, Yunzhong
    Feng, Jifeng
    Qin, Shukui
    Luo, Xiaoyan
    BMC CANCER, 2016, 16
  • [46] Efficacy and safety of amrubicin-based regimen used as first-line for extensive-disease small-cell lung cancer: A meta-analysis of randomized controlled trials
    Liu, Chun-Quan
    Tian, Dan
    Wang, Ning
    Meng, Xian-Pu
    Yang, Jian-Dong
    Li, Hua-Wei
    Zhao, Ning
    Zhao, Su
    Liao, Fei
    Cui, Yong
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (02) : E81 - E87
  • [47] Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposidecisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC)
    O'Brien, M.
    Jassem, J.
    Lorigan, P.
    Bosquee, L.
    Marshall, E.
    Bustin, F.
    Stigt, J.
    Dingemans, A. C.
    Hasan, B.
    Van Meerbeeck, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] Topotecan/Cisplatin Compared with Cisplatin/Etoposide as First-Line Treatment for Patients with Extensive Disease Small-Cell Lung Cancer Final Results of a Randomized Phase III Trial
    Fink, Thomas H.
    Huber, Rudolf M.
    Heigener, David F.
    Eschbach, Corrina
    Waller, Cornelius
    Steinhauer, Ernst U.
    Virchow, Johann C.
    Eberhardt, Frank
    Schweisfurth, Hans
    Schroeder, Michael
    Ittel, Thomas
    Hummler, Simone
    Banik, Norbert
    Bogenrieder, Thomas
    Acker, Thomas
    Wolf, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : 1432 - 1439
  • [49] Second-line chemotherapy with amrubicin for sensitive/refractory recurrent small-cell lung cancer (SCLC): A phase II study (#0301) by the thoracic oncology research group
    Takiguchi, Yuichi
    Masuda, Noriyuki
    Seto, Takashi
    Eguchi, Kenji
    Isobe, Hiroshi
    Okamoto, Hiroaki
    Ogura, Takashi
    Yokoyama, Akira
    Watanabe, Koshiro
    ANNALS OF ONCOLOGY, 2006, 17 : 220 - 220
  • [50] CheckMate 451: A randomized, double-blind, phase III trial of nivolumab (nivo), nivo plus ipilimumab (ipi), or placebo as maintenance therapy in patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC) after first-line platinum-based doublet chemotherapy (PT-DC)
    Ready, Neal
    Owonikoko, Taofeek Kunle
    Postmus, Pieter E.
    Reck, Martin
    Peters, Solange
    Pieters, Anne
    Selvaggi, Giovanni
    Fairchild, Justin P.
    Govindan, Ramaswamy
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345